The Protective Role of Bradykinin Potentiating Factor on Gastrointestinal Ulceration Induced by Indomethacin in Experimental Animals.

Although, indomethacin is used in the treatment of some diseases, it is associated with side effects. Therefore, this study evaluates the effect of bradykinin potentiating factor (BPF7) as a natural products separated from the venom of jellyfish, Cassiopia andromeda on indomethacin-induced gastrointestinal ulceration and to examine the possibility of gastric ulcer healing by this natural peptides. The present study demonstrated that oral administration of indomethacin (10mg/kg b.w) is associated with several adverse effects on stomach and intestine tissues which involve gastric and peptic ulceration, inflammation and mucosal injury. These histological changes were diminished or oblished by BPF7 treatment. In addition, indomethacin induced a significant increase in HcL, calcium, acid phosphatase and haemoglobin levels in gastric juice.While, the treatment with BPF7 showed a significant improvement of these parameters as compared with the model ulcer animals. The deleterious effects of indomethacin in this study may be due to a direct action of these drugs as a cytotoxic effect or that increase the epithelial permeability and inhibition of endogenous prostaglandins synthesis. On the other hand, the study suggests that BPF7 ameliorating the deleterious effects of indomethacin possibly by the direct effect of this factor which acts as Gastroprotective agent or indirect action through the stimulation of endogenous bradykinin which in turn enhances prostaglandins synthesis.